A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506354-20-00

Acronym

BP44382

Enrollment

Registered

2023-11-30

Start date

2024-02-20

Completion date

2025-03-04

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer and Neuroendocrine Carcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, France, Germany, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026